A detailed history of Nat West Group PLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Nat West Group PLC holds 14,235 shares of LLY stock, worth $11.1 Million. This represents 3.73% of its overall portfolio holdings.

Number of Shares
14,235
Previous 13,860 2.71%
Holding current value
$11.1 Million
Previous $12.5 Million 0.5%
% of portfolio
3.73%
Previous 4.32%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

BUY
$772.14 - $960.02 $289,552 - $360,007
375 Added 2.71%
14,235 $12.6 Million
Q2 2024

Jul 19, 2024

BUY
$724.87 - $909.04 $18,846 - $23,635
26 Added 0.19%
13,860 $12.5 Million
Q1 2024

Apr 19, 2024

SELL
$592.2 - $792.28 $693,466 - $927,759
-1,171 Reduced 7.8%
13,834 $10.8 Million
Q4 2023

Jan 12, 2024

SELL
$525.19 - $619.13 $1.23 Million - $1.44 Million
-2,333 Reduced 13.46%
15,005 $8.75 Million
Q3 2023

Oct 12, 2023

BUY
$434.7 - $599.3 $283,859 - $391,342
653 Added 3.91%
17,338 $9.31 Million
Q2 2023

Jul 25, 2023

BUY
$350.74 - $468.98 $67,692 - $90,513
193 Added 1.17%
16,685 $7.82 Million
Q1 2023

Apr 24, 2023

BUY
$310.63 - $364.82 $98,469 - $115,647
317 Added 1.96%
16,492 $5.66 Million
Q4 2022

Jan 27, 2023

BUY
$321.55 - $374.67 $19,614 - $22,854
61 Added 0.38%
16,175 $0
Q3 2022

Oct 31, 2022

BUY
$296.48 - $337.87 $4.78 Million - $5.44 Million
16,114 New
16,114 $5.21 Million
Q1 2021

Apr 16, 2021

SELL
$164.32 - $212.72 $493,452 - $638,798
-3,003 Closed
0 $0
Q4 2020

Feb 04, 2021

SELL
$130.46 - $172.63 $382,639 - $506,323
-2,933 Reduced 49.41%
3,003 $508,000
Q2 2020

Jul 16, 2020

SELL
$136.42 - $164.18 $100,405 - $120,836
-736 Reduced 11.03%
5,936 $975,000
Q1 2020

May 07, 2020

BUY
$119.05 - $147.35 $87,620 - $108,449
736 Added 12.4%
6,672 $926,000
Q3 2019

Oct 24, 2019

SELL
$106.79 - $116.16 $80,092 - $87,120
-750 Reduced 11.22%
5,936 $664,000
Q2 2019

Jul 25, 2019

BUY
$110.79 - $129.32 $157,875 - $184,281
1,425 Added 27.09%
6,686 $741,000
Q1 2019

May 08, 2019

SELL
$111.31 - $131.02 $461,936 - $543,733
-4,150 Reduced 44.1%
5,261 $682,000
Q4 2018

Feb 12, 2019

SELL
$105.9 - $118.64 $247,594 - $277,380
-2,338 Reduced 19.9%
9,411 $1.09 Million
Q3 2018

Nov 13, 2018

SELL
$85.86 - $107.31 $78,991 - $98,725
-920 Reduced 7.26%
11,749 $1.26 Million
Q2 2018

Aug 13, 2018

SELL
$75.7 - $86.88 $7,570 - $8,688
-100 Reduced 0.78%
12,669 $1.08 Million
Q1 2018

May 14, 2018

SELL
$74.21 - $87.6 $106,120 - $125,267
-1,430 Reduced 10.07%
12,769 $988,000
Q4 2017

Feb 06, 2018

SELL
$81.94 - $87.89 $310,552 - $333,103
-3,790 Reduced 21.07%
14,199 $1.2 Million
Q3 2017

Nov 14, 2017

SELL
$77.07 - $85.54 $2.44 Million - $2.71 Million
-31,719 Reduced 63.81%
17,989 $1.54 Million
Q2 2017

Aug 14, 2017

BUY
N/A
49,708
49,708 $4.09 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $740B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Nat West Group PLC Portfolio

Follow Nat West Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nat West Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Nat West Group PLC with notifications on news.